{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:46:06Z","timestamp":1785228366807,"version":"3.55.0"},"reference-count":36,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: While the clinical application of SII-ONCO-Bacillus Calmette\u2013Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) is well established in Greece, there is a lack of real-world data on its effectiveness and safety. This retrospective, observational, multicenter, chart-review study aims to provide real-life data on the effectiveness and safety of SII-ONCO-BCG in patients with intermediate- and high-risk NMIBC. Methods: From January 2016 to December 2023, medical records from six hospital centers were reviewed for adult patients with histologically confirmed stage Ta or T1 NMIBC (with or without carcinoma in situ [CIS]) who received at least one maintenance course of SII-ONCO-BCG after induction. Tumor recurrence and progression were monitored at scheduled time intervals. Primary outcomes included recurrence-free survival (RFS) and progression-free survival (PFS), while adverse events (AEs) constituted secondary outcomes. Results: A total of 162 patients receiving SII-ONCO-BCG were enrolled. Among all patients, 145 (89.5%) patients were men, 88 (54.3%) aged 70 years or older, 103 (63.6%) had T1, 43 (26.5%) Ta, and 21 (12.9%) concurrent CIS. The median follow-up duration was 28.9 months (range, 5\u201336) and the mean BCG intravesical instillation courses were 13.7 (range, 9\u201327). After 3-, 2-, and 1-year follow-up, RFS rates of 85.2% (95% CI, 79.7\u201390.7%), 85.8% (80.4\u201391.2%), and 87.0% (81.8\u201392.3%) were observed, respectively. The corresponding 3-, 2-, and 1-year PFS rates were 96.9% (94.2\u201399.6%), 96.9% (94.2\u201399.6%), and 97.5% (95.1\u201399.9%), respectively. During the whole follow-up period, 24 (14.8%) patients experienced at least one AE. Conclusions: This real-world study demonstrates that SII-ONCO-BCG is an effective and safe treatment for patients with intermediate- and high-risk NMIBC.<\/jats:p>","DOI":"10.3390\/curroncol32010018","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:34:19Z","timestamp":1735630459000},"page":"18","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette\u2013Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece"],"prefix":"10.3390","volume":"32","author":[{"given":"Panagiotis","family":"Angelopoulos","sequence":"first","affiliation":[{"name":"2nd Department of Urology, Sismanogleio Hospital, Medical School, National and Kapodistrian University of Athens, 15126 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titos","family":"Markopoulos","sequence":"additional","affiliation":[{"name":"2nd Department of Urology, Sismanogleio Hospital, Medical School, National and Kapodistrian University of Athens, 15126 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4979-6452","authenticated-orcid":false,"given":"Lazaros","family":"Lazarou","sequence":"additional","affiliation":[{"name":"2nd Department of Urology, Sismanogleio Hospital, Medical School, National and Kapodistrian University of Athens, 15126 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Skolarikos","sequence":"additional","affiliation":[{"name":"2nd Department of Urology, Sismanogleio Hospital, Medical School, National and Kapodistrian University of Athens, 15126 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5828-8197","authenticated-orcid":false,"given":"Panagiotis","family":"Stamatakos","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Athens G. Gennimatas, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios I.","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Athens G. Gennimatas, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Fragkoulis","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Athens G. Gennimatas, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Ntoumas","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Athens G. Gennimatas, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1820-9027","authenticated-orcid":false,"given":"Napoleon","family":"Moulavasilis","sequence":"additional","affiliation":[{"name":"1st Department of Urology, \u201cLaiko\u201d Gen. Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Levis","sequence":"additional","affiliation":[{"name":"1st Department of Urology, \u201cLaiko\u201d Gen. Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6669-5982","authenticated-orcid":false,"given":"Dimitrios","family":"Papanikolaou","sequence":"additional","affiliation":[{"name":"2nd Urology Department of Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Sokolakis","sequence":"additional","affiliation":[{"name":"2nd Urology Department of Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Hatzimouratidis","sequence":"additional","affiliation":[{"name":"2nd Urology Department of Medical School, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Tzanetakos","sequence":"additional","affiliation":[{"name":"Health Through Evidence, 17456 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Psarra","sequence":"additional","affiliation":[{"name":"Health Through Evidence, 17456 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9357-4788","authenticated-orcid":false,"given":"George","family":"Mavridoglou","sequence":"additional","affiliation":[{"name":"Department of Accounting and Finance, School of Management, University of the Peloponnese, 24150 Kalamata, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0031-8591","authenticated-orcid":false,"given":"Konstantinos","family":"Skriapas","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Larissa, 41334 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4051-2388","authenticated-orcid":false,"given":"Dimitra","family":"Akrivou","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Larissa, 41334 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Karagiannis","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital of Larissa, 41334 Larissa, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Noutsos","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital G. Hatzikosta, 45445 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Georgiou","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital G. Hatzikosta, 45445 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Hastazeris","sequence":"additional","affiliation":[{"name":"Department of Urology, General Hospital G. Hatzikosta, 45445 Ioannina, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7239-9829","authenticated-orcid":false,"given":"George","family":"Gourzoulidis","sequence":"additional","affiliation":[{"name":"Health Through Evidence, 17456 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Mitropoulos","sequence":"additional","affiliation":[{"name":"1st Department of Urology, \u201cLaiko\u201d Gen. Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eursup.2009.06.009","article-title":"Intravesical Instillation Treatment of Non\u2013Muscle-Invasive Bladder Cancer","volume":"8","author":"Braasch","year":"2009","journal-title":"Eur. Urol. Suppl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/j.1464-410X.2008.07968.x","article-title":"Risk-Adapted Use of Intravesical Immunotherapy","volume":"102","author":"Braasch","year":"2008","journal-title":"BJU Int."},{"key":"ref_4","first-page":"e076743","article-title":"Advances in Diagnosis and Treatment of Bladder Cancer","volume":"384","author":"Cookson","year":"2024","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1086\/314064","article-title":"Efficacy and Safety of Bacille Calmette-Gu\u00e9rin Immunotherapy in Superficial Bladder Cancer","volume":"31","author":"Lamm","year":"2000","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: Aua\/Suo Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Tat1 and Carcinoma in Situ)\u2014A Summary of the 2024 Guidelines Update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/iju.13410","article-title":"Intravesical Bacillus Calmette\u2013Gu\u00e9rin Instillation in Non-Muscle-Invasive Bladder Cancer: A Review","volume":"25","author":"Saluja","year":"2018","journal-title":"Int. J. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","article-title":"Long-Term Results of Intravesical Therapy for Superficial Bladder Cancer","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Guerin Immunotherapy for Recurrent Ta, T1 and Carcinoma in Situ Transitional Cell Carcinoma of the Bladder: A Randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0022-5347(01)65936-6","article-title":"Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Prophylaxis for Recurrent Papillary (Stages Ta to T1) Superficial Bladder Cancer. Finnbladder Group","volume":"156","author":"Rintala","year":"1996","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A Prospective Comparative Study of Intravesical Bacillus Calmette-Gu\u00e9rin Therapy with the Tokyo or Connaught Strain for Nonmuscle Invasive Bladder Cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Farah, N.B., Ghanem, R., and Amr, M. (2014). Treatment Efficacy and Tolerability of Intravesical Bacillus Calmette-Guerin (Bcg)-Rivm Strain: Induction and Maintenance Protocol in High Grade and Recurrent Low Grade Non-Muscle Invasive Bladder Cancer (Nmibc). BMC Urol., 14.","DOI":"10.1186\/1471-2490-14-11"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-Analysis of the Published Results of Randomized Clinical Trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-Muscle-Invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"484.e419","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The Efficacy of Bcg Tice and Bcg Connaught in a Cohort of 2,099 Patients with T1g3 Non-Muscle-Invasive Bladder Cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.urolonc.2020.01.002","article-title":"A Prospective Comparative Study to Assess the Efficacy and Tolerability of 2 Different Doses of Intravesical Bacillus Calmette-Guerin (Bcg) in Patients with Non-Muscle-Invasive Bladder Cancer","volume":"38","author":"Sood","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_19","unstructured":"Stephen Jones, J. (2016). Non\u2013Muscle-Invasive Bladder Cancer (Ta, T1, and CIS). Campbell-Walsh Urology, Elsevier. [11th ed.]. Chapter 93."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin Immunotherapy of Superficial Bladder Cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin Versus Chemotherapy for the Intravesical Treatment of Patients with Carcinoma in Situ of the Bladder: A Meta-Analysis of the Published Results of Randomized Clinical Trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J. Urol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJM199110243251703","article-title":"A Randomized Trial of Intravesical Doxorubicin and Immunotherapy with Bacille Calmette-Gu\u00e9rin for Transitional-Cell Carcinoma of the Bladder","volume":"325","author":"Lamm","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical Bacillus Calmette-Guerin Versus Mitomycin C for Superficial Bladder Cancer: A Formal Meta-Analysis of Comparative Studies on Recurrence and Toxicity","volume":"169","author":"Jocham","year":"2003","journal-title":"J. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Del Giudice, F., Asero, V., Bologna, E., Scornajenghi, C.M., Carino, D., Dolci, V., Viscuso, P., Salciccia, S., Sciarra, A., and D\u2019Andrea, D. (2023). Efficacy of Different Bacillus of Calmette-Gu\u00e9rin (Bcg) Strains on Recurrence Rates among Intermediate\/High-Risk Non-Muscle Invasive Bladder Cancers (Nmibcs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15071937"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e8300","DOI":"10.1097\/MD.0000000000008300","article-title":"Dose, Duration and Strain of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: Meta-Analysis of Randomized Clinical Trials","volume":"96","author":"Quan","year":"2017","journal-title":"Medicine"},{"key":"ref_26","first-page":"590","article-title":"Adjuvant Intravesical Treatment for Nonmuscle Invasive Bladder Cancer: The Importance of the Strain and Maintenance","volume":"41","year":"2017","journal-title":"Actas Urol. Esp."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cncr.23627","article-title":"Maintenance Bacillus Calmette-Gu\u00e9rin in High-Risk Nonmuscle-Invasive Bladder Cancer: How Much Is Enough?","volume":"113","author":"Decobert","year":"2008","journal-title":"Cancer"},{"key":"ref_28","first-page":"E54","article-title":"Are There Differences among Bacillus Calmette-Gu\u00e9rin (Bcg) Strains Regarding Their Clinical Efficacy in the Treatment of Non-Muscleinvasive Bladder Cancer? The Jury Is Still out but the Answer Is Likely No","volume":"14","author":"Tan","year":"2020","journal-title":"Can. Urol. Assoc. J. J. L\u2019association Urol. Can."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.juro.2012.09.049","article-title":"Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-Gu\u00e9rin Substrains","volume":"189","author":"Luquin","year":"2013","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajur.2021.05.002","article-title":"Intravesical Bacillus Calmette-Guerin (Bcg) in Treating Non-Muscle Invasive Bladder Cancer-Analysis of Adverse Effects and Effectiveness of Two Strains of Bcg (Danish 1331 and Moscow-I)","volume":"9","author":"Thyavihally","year":"2022","journal-title":"Asian J. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/JCMA.0000000000000768","article-title":"The Comparison of Different Bcg Strains in the Intravesical Treatment of Non-Muscle Invasive Urothelial Carcinoma of Urinary Bladder-a Real-World Practice","volume":"85","author":"Chen","year":"2022","journal-title":"J. Chin. Med. Assoc. JCMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1309532","DOI":"10.3389\/fruro.2024.1309532","article-title":"Outcomes of Intravesical Bacillus Calmette-Guerin in Patients with Non-Muscle Invasive Bladder Cancer: A Retrospective Study in Australia","volume":"4","author":"Haghighi","year":"2024","journal-title":"Front. Urol."},{"key":"ref_33","first-page":"238","article-title":"Safety and Efficacy of Various Strains of Bacille Calmette-Gu\u00e9rin in the Treatment of Bladder Tumours in Standard Clinical Practice","volume":"42","year":"2018","journal-title":"Actas Urol. Esp."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12301-020-00099-6","article-title":"Complications of Intravesical Bcg Therapy in Non-Muscle Invasive Bladder Cancer: Our Tertiary Care Centre Experience","volume":"26","author":"Sharma","year":"2020","journal-title":"Afr. J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer","volume":"25","author":"Chang","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fan, J., Chen, B., Luo, Q., Li, J., Huang, Y., Zhu, M., Chen, Z., Li, J., Wang, J., and Liu, L. (2024). Potential Molecular Biomarkers for the Diagnosis and Prognosis of Bladder Cancer. Biomed. Pharmacother. Biomed. Pharmacother., 173.","DOI":"10.1016\/j.biopha.2024.116312"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/1\/18\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:56Z","timestamp":1760115356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/1\/18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["curroncol32010018"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32010018","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}